India, Oct. 30 -- The biotech sector stayed active this week, with a mix of regulatory approvals, strategic partnerships, M&A activity, and clinical trial developments.
Companies secured new approvals across oncology, immunology and medical technology, while several firms advanced drug-development programs through licensing deals, AI-driven research collaborations and acquisitions.
On the clinical front, AbbVie reported positive Phase 3 migraine data for QULIPTA, Genmab's petosemtamab combination improved survival in head and neck cancer, and Benitec reported encouraging interim results for BB-301, while Geron discontinued its phase 3 IMpactMF trial after an independent monitoring committee recommended it.
Let us unpack the specifics.
A...